The first patient has been dosed in a phase 2b clinical trial of OCS-01 for the treatment of inflammation and pain after cataract surgery, Oculis announced in a press release.
OCS-01 is a proprietary topical nanoparticle formulation of dexamethasone based on Oculus’ solubilizing nanoparticle (SNP) technology platform. The prospective, multicenter, randomized phase 2b clinical trial is evaluating safety and efficacy.
“Our SNP platform enables us to formulate topical therapeutics for delivery to both the back and front of the eye,” Riad Sherif, MD, CEO of Oculis, said in the
Uncategorized